Alnylam data on ATTR-CM drug Vutrisiran are eagerly awaited

Next week, the biopharma world will see highly anticipated results from a study that could transform the way patients with an increasingly common heart disease are treated – and determine which companies will rake in billions.

The trial of Vutrisiran from Alnylam Pharmaceuticals has already been classified as positive. The drug successfully reduced the risk of death and cardiovascular complications in patients with the disease transthyretin amyloid cardiomyopathy (ATTR-CM). Given the strong data, the RNA interference therapy is expected to receive approval.

But Alnylam's drug is not the only option for patients. Pfizer has two competing therapies on offer, and BridgeBio has one that is close to approval. Investors and cardiologists are eagerly awaiting the full results of Alnylam's HELIOS-B trial, which are due to be presented next Friday, August 30, in London at the annual meeting of the European Society of Cardiology.